These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22681244)

  • 41. Progression of haemophilic arthropathy in children: a Lithuanian--Danish comparative study.
    Saulyte Trakymiene S; Clausen N; Poulsen LH; Ingerslev J; Rageliene L
    Haemophilia; 2013 Mar; 19(2):212-8. PubMed ID: 23167920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prophylaxis in haemophilia B. Prevention of bleeds and FIX consumption].
    Siegmund B; Richter H; Pollmann H
    Hamostaseologie; 2010 Nov; 30 Suppl 1():S35-8. PubMed ID: 21042666
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Secondary prophylaxis in an adult patient with severe haemophilia A. Factor VIII consumption and effectiveness.
    Schlenkrich S; Schubert C
    Hamostaseologie; 2013 Aug; 33(3):241-4. PubMed ID: 23435748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
    Nilsson IM; Berntorp E; Löfqvist T; Pettersson H
    J Intern Med; 1992 Jul; 232(1):25-32. PubMed ID: 1640190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K; Walker I; Decker K; Chan AK; Pai MK
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary prophylaxis in children with haemophilia.
    Coppola A; Di Capua M; De Simone C
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s4-11. PubMed ID: 19105503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
    Steen Carlsson K; Höjgård S; Glomstein A; Lethagen S; Schulman S; Tengborn L; Lindgren A; Berntorp E; Lindgren B
    Haemophilia; 2003 Sep; 9(5):555-66. PubMed ID: 14511294
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
    Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
    Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
    van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
    Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Haemophilia prophylaxis in young patients--a long-term follow-up.
    Löfqvist T; Nilsson IM; Berntorp E; Pettersson H
    J Intern Med; 1997 May; 241(5):395-400. PubMed ID: 9183307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prophylaxis in people with haemophilia.
    Coppola A; Franchini M; Tagliaferri A
    Thromb Haemost; 2009 Apr; 101(4):674-81. PubMed ID: 19350110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
    Rizza CR; Kernoff PB; Matthews JM; McLennan CR; Rainsford SG
    Thromb Haemost; 1977 Feb; 37(1):86-90. PubMed ID: 320712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study.
    Gringeri A; Leissinger C; Cortesi PA; Jo H; Fusco F; Riva S; Antmen B; Berntorp E; Biasoli C; Carpenter S; Kavakli K; Morfini M; Négrier C; Rocino A; Schramm W; Windyga J; Zülfikar B; Mantovani LG
    Haemophilia; 2013 Sep; 19(5):736-43. PubMed ID: 23731246
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
    Walsh CE; Valentino LA
    Haemophilia; 2009 Sep; 15(5):1014-21. PubMed ID: 19493018
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
    Oldenburg J; Carcao M; Lentz SR; Mahlangu J; Mancuso ME; Matsushita T; Négrier C; Clausen WHO; Ehrenforth S; Young G
    Haemophilia; 2018 Nov; 24(6):911-920. PubMed ID: 30248217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prophylaxis and continuous infusion for hemophilia: can we afford it?
    Aledort LM; Bohn RL
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S35-7. PubMed ID: 8735795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
    Khawaji M; Astermark J; Berntorp E
    Eur J Haematol; 2012 Apr; 88(4):329-35. PubMed ID: 22221195
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C; Young G
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.